Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7831473 | 1.00 | CHRNA7 (0.52) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 | |
| SCHEMBL6950222 | 1.00 | CHRNA7 (0.52) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 | |
| SCHEMBL5016747 | 0.91 | CHRNA7 (0.57) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 | |
| SCHEMBL8477435 | 0.88 | CHRNA7 (0.50) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 | |
| SCHEMBL10034621 | 0.84 | TDP1 (0.54) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 | |
| SCHEMBL6950753 | 0.84 | TDP1 (0.54) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 | |
| SCHEMBL6946868 | 0.84 | CHRNA7 (0.50) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 | |
| SCHEMBL23655466 | 0.83 | CHRNA7 (0.57) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL6014385 | 0.83 | TDP1 (0.53) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 | |
| SCHEMBL6014381 | 0.83 | CHRNA7 (0.62) | CHRNA7KDM4ECYP2A6TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1074544-A1 | Process for production of 3-(3-pyridyl)-1-propanol derivatives | KANEKA CORPORATION (JP) | 2001-02-07 | — | — | EP | claimed |
| US-5977105-A | Compounds | ASTRA PHARMAEUTICALS LTD. (GB) | 1999-11-02 | — | — | US | claimed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-1074544-B1 | Process for production of 3-(3-pyridyl)-1-propanol derivatives | KANEKA CORP (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-6388086-B1 | REACTING W 3-METHYLPYRIDINE WITH BASE; THEN EPOXY COMPOUND | KANEKA CORPORATION (JP) | 2002-05-14 | — | — | US | disclosed |
| US-6265409-B1 | ANTIINFLAMMATORY AGENTS | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1115401-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| EP-1115705-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| EP-1115706-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| EP-0984961-B1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000018736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018730-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018731-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| EP-0984961-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astra Pharmaceuticals Limited (GB) | 2000-03-15 | — | — | EP | disclosed |
| US-5977105-A | Compounds | ASTRA PHARMAEUTICALS LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| WO-1998043971-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998042669-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-01 | — | — | WO | disclosed |
| EP-0865431-A2 | COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997020815-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | CHRNA7 4874/4885KDM4E 858/4885CYP2A6 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.